Akari Therapeutics $AKTX stock rose 41% today after the company announced the appointment of Dr. Patricia LoRusso, a leading figure in oncology, to its Scientific Advisory Board.


H.C. Wainwright reiterated his "BUY" recommendation for the stock, setting a target price of $27.00, well above current levels.
post-image
post-image
post-image
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned